Predictors and Targets of Response to Cytokine Antagonism in Depression
Predictors and Targets of Response to Cytokine Antagonism in Depression
批准号:
8489793
负责人:
ANDREW H MILLER
金额:
$7.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2015-03-31
关键词:
AcuteAdultAnhedoniaAnti-Cytokine TherapyAnti-Inflammatory AgentsAnti-inflammatoryAntidepressive AgentsBasal GangliaBehavioralBiological AssayBlood specimenChronicClinicalClinical TrialsCrohn&aposs diseaseDataDepressed moodDiseaseDouble-Blind MethodEconomic BurdenExhibitsFatigueFundingFutureHamilton Rating Scale for DepressionHealth Care CostsHourHydrocortisoneImmuneImmune TargetingIndividualInflammationInflammatoryInflammatory ResponseInfusion proceduresKynurenineLinkMajor Depressive DisorderMeasuresMental DepressionMonoclonal AntibodiesMorbidity - disease rateNecrosisNeurobiologyNeurocognitiveNeuropsychological TestsPathway interactionsPatientsPharmaceutical PreparationsPlacebo ControlPlacebo EffectPlacebosPlasmaPolysomnographyProteinsPublic HealthRandomizedResearchResistanceSamplingSleepSlow-Wave SleepSpeedSymptomsTestingTherapy Clinical TrialsTimeTryptophanTumor Necrosis Factor-alphaUlcerative ColitisUnited States National Institutes of Healthbasebrain behaviorcytokinedepressive symptomsdesigndisabilitydouble-blind placebo controlled trialhypothalamic-pituitary-adrenal axisinflammatory markerinfliximabmortalityneurocognitive testpatient populationperipheral bloodpublic health relevanceresponsetreatment effecttreatment responsetreatment trialtumorweek trial
中文摘要
描述(由申请人提供):该项目旨在确定治疗难治性抑郁症(TRD)患者对细胞因子拮抗反应的预测因素和目标。长期目标是基于与炎症相关的明确的病理生理机制,开发个性化的策略来治疗患者群体和症状领域。拟议的研究结果将有助于在未来的研究中告知哪些病理生理学领域,从而哪些患者群体最有可能对包括细胞因子拮抗在内的抗炎策略做出反应。美国约2000万人中高达三分之一
患有严重抑郁症的成年人无法对传统的抗抑郁药物治疗产生反应,导致长期残疾、发病率和死亡率增加,并带来巨大的经济负担。炎症可能是导致TRD的一条病理生理途径。炎症标志物的增加预示着治疗无反应,而与治疗耐药有关的临床因素与炎症增加有关。此外,炎性细胞因子可以破坏和绕过传统抗抑郁药物的作用机制。我们小组最近完成的一项由美国国立卫生研究院资助的双盲安慰剂对照试验(n=60)显示,在血浆高敏C反应蛋白5 mg/L(n=22,占样本的37%)反映的高基线炎症的TRD患者中,3次注射有效的抗细胞因子治疗英夫利昔单抗(5 mg/kg)比安慰剂有更大的抗抑郁反应。英夫利昔单抗是一种针对炎性细胞因子肿瘤坏死因子(TNF)-α的单抗,已被证明在重度抑郁症患者中可靠地升高。作为试验的一部分,我们收集了大量的额外数据和样本(不是最初NIH研究的一部分),包括多个症状领域的测量、神经认知测试、多导睡眠图,以及可以分析犬尿氨酸(KYN)途径激活和白天下丘脑-垂体-肾上腺(HPA)轴活动的系列血液样本。这些额外的数据是在基线、第一次输液后24小时和12周试验的第8周收集的。在目前的研究中,我们建议测试和分析这些样本和数据,并利用结果来阐明预测英夫利昔单抗治疗成功并对其做出反应的病理生理领域,英夫利昔单抗治疗成功的患者(n=15)占英夫利昔单抗治疗患者的50%。根据以往细胞因子对大脑和行为影响的研究,我们假设基底节功能、睡眠、KYN通路激活和HPA轴活动将是预测和响应英夫利昔单抗急性(24小时内)和慢性给药的相关病理生理学区域。为了验证这些假设,英夫利昔单抗与安慰剂应答者和无应答者的症状数据、神经心理测试、多导睡眠图和外周血液中血浆色氨酸、KYN和皮质醇的测量进行了比较。这些数据将提供有关细胞因子拮抗反应的相关预测因子和靶点的重要线索,并将为未来基于免疫的治疗试验的设计提供信息。
英文摘要
DESCRIPTION (provided by applicant): This project is designed to identify the predictors and targets of response to cytokine antagonism in patients with treatment resistant depression (TRD). The long term objectives are to develop personalized strategies to treat patient populations and symptom domains based on defined pathophysiologic mechanisms related to inflammation. The results of the proposed research will help inform which pathophysiologic domains and therefore which patient populations are most likely to respond to anti-inflammatory strategies including cytokine antagonism in future studies. Up to one third of the ~20 million U.S.
adults with major depression are unable to respond to conventional antidepressant therapy, leading to prolonged disability, increased morbidity and mortality and significant economic burden. One pathophysiologic pathway that may contribute to TRD is inflammation. Increased inflammatory markers predict treatment non-response, and clinical factors linked with treatment resistance are associated with increased inflammation. In addition, inflammatory cytokines can sabotage and circumvent mechanisms of action of conventional antidepressant medications. A recently completed NIH-funded, double-blind, placebo-controlled trial (n=60) conducted by our group has shown that 3 infusions of the potent anti-cytokine therapy infliximab (5mg/kg) led to a greater antidepressant response than placebo in TRD patients with high baseline inflammation as reflected by a plasma high sensitivity c-reactive protein >5mg/L (n=22, representing 37% of the sample). Infliximab is a monoclonal antibody that targets the inflammatory cytokine, tumor necrosis factor (TNF)-alpha, which has been shown to be reliably elevated in patients with major depression. As part of the trial, we gathered extensive additional data and samples (which were not part of the original NIH study) including measures of multiple symptom domains, neurocognitive testing, polysomnography, and serial blood samples that can be assayed for kynurenine (KYN) pathway activation and diurnal hypothalamic-pituitary-adrenal (HPA) axis activity. This additional data was collected at baseline, 24 hrs after the first infusion and at Wek 8 of the 12 week trial. In the current study, we propose to assay and analyze these samples and data and use the results to elucidate the pathophysiologic domains that predict and respond to successful infliximab treatment, which represented 50% of infliximab-treated patients (n=15). Based on previous studies of the impact of cytokines on the brain and behavior, we hypothesize that basal ganglia function, sleep, KYN pathway activation and HPA axis activity will be relevant pathophysiologic domains that will predict and respond to acute (within 24 hrs) and chronic administration of infliximab. To test these hypotheses, symptom data, neuropsychological testing, polysomnography and peripheral blood measures of plasma tryptophan, KYN and cortisol will be compared in infliximab vs. placebo responders and non-responders. These data will provide important clues regarding relevant predictors and targets of response to cytokine antagonism and will inform the design of future immune-based therapeutic trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using Human iPSC Models to Determine the Mechanism of Inflammation-Induced Disruption of Dopamine Neurotransmission
-
批准号:10575155
-
项目类别:
-
资助金额:$23.48万
-
财政年份:2022
-
负责人:ANDREW H MILLER
-
依托单位:
Using Human iPSC Models to Determine the Mechanism of Inflammation-Induced Disruption of Dopamine Neurotransmission
-
批准号:10707196
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2022
-
负责人:ANDREW H MILLER
-
依托单位:
Emory Psychiatry Clinical Scientist Training Program (CSTP)
-
批准号:8894612
-
项目类别:
-
资助金额:$21.49万
-
财政年份:2014
-
负责人:ANDREW H MILLER
-
依托单位:
Emory Psychiatry Clinical Scientist Training Program (CSTP)
-
批准号:8751923
-
项目类别:
-
资助金额:$21.43万
-
财政年份:2014
-
负责人:ANDREW H MILLER
-
依托单位:
Inflammation-Induced CNS Glutamate During Breast Cancer Treatment
-
批准号:8815732
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2014
-
负责人:ANDREW H MILLER
-
依托单位:
Predictors and Targets of Response to Cytokine Antagonism in Depression
-
批准号:8641432
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2013
-
负责人:ANDREW H MILLER
-
依托单位:
Phenotyping Major Depression with Increased Inflammation
-
批准号:7986778
-
项目类别:
-
资助金额:$44.34万
-
财政年份:2010
-
负责人:ANDREW H MILLER
-
依托单位:
Phenotyping Major Depression with Increased Inflammation
-
批准号:8438483
-
项目类别:
-
资助金额:$41.3万
-
财政年份:2010
-
负责人:ANDREW H MILLER
-
依托单位:
Phenotyping Major Depression with Increased Inflammation
-
批准号:8098152
-
项目类别:
-
资助金额:$43.6万
-
财政年份:2010
-
负责人:ANDREW H MILLER
-
依托单位:
Phenotyping Major Depression with Increased Inflammation
-
批准号:8257183
-
项目类别:
-
资助金额:$43.31万
-
财政年份:2010
-
负责人:ANDREW H MILLER
-
依托单位:
Phenotyping Major Depression with Increased Inflammation
-
批准号:8625336
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2010
-
负责人:ANDREW H MILLER
-
依托单位:
Dopaminergic Mechanisms of Cytokine-Induced Behavioral Change
-
批准号:7862584
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:ANDREW H MILLER
-
依托单位:
Dopaminergic Mechanisms of Cytokine-Induced Behavioral Change
-
批准号:8037711
-
项目类别:
-
资助金额:$38.36万
-
财政年份:2009
-
负责人:ANDREW H MILLER
-
依托单位:
Dopaminergic Mechanisms of Cytokine-Induced Behavioral Change
-
批准号:7655004
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2009
-
负责人:ANDREW H MILLER
-
依托单位:
Annual Mentoring Program in PsychoNeuroImmunology Research
-
批准号:7675102
-
项目类别:
-
资助金额:$2.6万
-
财政年份:2009
-
负责人:ANDREW H MILLER
-
依托单位:
Dopaminergic Mechanisms of Cytokine-Induced Behavioral Change
-
批准号:8225333
-
项目类别:
-
资助金额:$38.36万
-
财政年份:2009
-
负责人:ANDREW H MILLER
-
依托单位:
Dev Proj 4: Identifying IFN-alpha-Induced Microglial Activation Using...
-
批准号:7287021
-
项目类别:
-
资助金额:$3.82万
-
财政年份:2007
-
负责人:ANDREW H MILLER
-
依托单位:
Cytokine Induced Depression
-
批准号:7553552
-
项目类别:
-
资助金额:$23.76万
-
财政年份:2007
-
负责人:ANDREW H MILLER
-
依托单位:
Psychoimmunology
-
批准号:7485209
-
项目类别:
-
资助金额:$17.41万
-
财政年份:2007
-
负责人:ANDREW H MILLER
-
依托单位:
Neuroimmune Mechanisms of Glucocorticoid Resistance
-
批准号:7406095
-
项目类别:
-
资助金额:$19.61万
-
财政年份:2006
-
负责人:ANDREW H MILLER
-
依托单位:
海外基金